Progenza OA Kyocera Negotiations Update
Under the terms of the MOU signed with Kyocera on 2 March 2020, Kyocera has exclusive rights to negotiate a commercial licence for Progenza in Japan. Under the terms of the MOU, that period of exclusivity currently extends to the end of July 2020.
The negotiations have progressed positively with a view on agreeing final terms. Both parties remain committed to the proposed commercial licence and the parties have agreed to extend the period of exclusivity, such that Kyocera will continue to have exclusive rights to negotiate the licence until 31 August 2020.
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology.